Psychiatry Center of Excellence

Supporting patients living with a rare or complex psychiatric condition

Orsini’s Psychiatry Center of Excellence launched in 2016 with our first program for shizophrenia. Today we support multiple psychiatry programs across several rare and complex conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Psychiatric Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Psychiatry Conditions Supported

Explore the psychiatry conditions Orsini supports below.

About Alcohol Dependence

Alcohol dependence is a chronic and debilitating condition marked by a compulsive need for alcohol consumption despite adverse consequences. Individuals with this disorder develop a tolerance, necessitating increased alcohol intake to experience the desired effects. The inability to control or limit drinking, coupled with withdrawal symptoms when not drinking, characterizes alcohol dependence. It adversely affects physical health, mental well-being, and social relationships, often leading to a cycle of escalating consumption.

Alcohol Dependence Therapies Supported

Full Name	Vivitrol® (naltrexone)
Drug	Vivitrol
Manufacturer	Alkermes
Route of Administration	Intramuscular
Site of Care	Healthcare Facility
Approved Indication	The treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL; The prevention of relapse to opioid dependence following opioid detoxification
Disease	Alcohol Dependence; Opioid Dependence
Therapeutic Area	Mental Health & Addiction
Enrollment Form Link	Vivitrol Enrollment Form
Phone Number	800-373-1406
Fax Number	847-427-7975, 855-677-4641, 877-496-3716
Product Website	vivitrolhcp.com

About Bipolar Disorder

Bipolar disorder is a mental health condition characterized by extreme mood swings between manic and depressive states. During manic episodes, individuals may experience heightened energy, impulsivity, and euphoria. Depressive phases involve intense sadness, fatigue, and feelings of worthlessness. These mood shifts can significantly impact daily life, relationships, and overall functioning. The exact cause is complex, involving genetic and environmental factors.

Bipolar Disorder Therapies Supported

Abilify MyCite® (aripiprazole tablets with sensor)

Full Name	Abilify MyCite® (aripiprazole tablets with sensor)
Drug	Abilify MyCite
Manufacturer	Otsuka Pharmaceutical Co., Ltd.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of adults with schizophrenia, bipolar I disorder, and adjunctive treatment of adults with major depressive disorder (MDD)
Disease	Schizophrenia; Bipolar Disorder; Major Depressive Disorder (MDD)
Therapeutic Area	Psychiatry, Mental Health & Addiction
Enrollment Form Link	Enrollment Form
Phone Number	844-692-4833
Fax Number	847-789-9274
Product Website	abilifymycitehcp.com

About Huntington’s Disease Chorea

Huntington’s disease chorea is a progressive neurodegenerative disorder characterized by involuntary, jerky movements known as chorea. This hereditary condition results from a mutation in the HTT gene, leading to the degeneration of nerve cells in the brain. Chorea involves random, uncontrollable muscle contractions, affecting coordination and voluntary movements. As Huntington’s disease advances, it causes cognitive decline, emotional disturbances, and impaired motor skills. The relentless nature of chorea significantly impacts an individual’s quality of life, requiring comprehensive support and care.

Huntington’s Disease Chorea Therapies Supported

Full Name	Austedo® (deutetrabenazine)
Drug	Austedo
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	austedohcp.com

Full Name	Austedo® XR (deutetrabenazine)
Drug	Austedo XR Extended Release
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	www.austedohcp.com

Full Name	Ingrezza® (valbenazine)
Drug	Ingrezza
Manufacturer	Neurocrine Biosciences
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of adults with tardive dyskinesia or chorea associated with Huntington’s disease
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-279-1676
Fax Number	877-868-1681
Product Website	ingrezzahcp.com

About Major Depressive Disorder (MDD)

Major Depressive Disorder is a common mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. It often involves changes in appetite, sleep patterns, and concentration, affecting daily functioning.

MDD Therapies Supported

Full Name	Abilify MyCite® (aripiprazole tablets with sensor)
Drug	Abilify MyCite
Manufacturer	Otsuka Pharmaceutical Co., Ltd.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of adults with schizophrenia, bipolar I disorder, and adjunctive treatment of adults with major depressive disorder (MDD)
Disease	Schizophrenia; Bipolar Disorder; Major Depressive Disorder (MDD)
Therapeutic Area	Psychiatry, Mental Health & Addiction
Enrollment Form Link	Enrollment Form
Phone Number	844-692-4833
Fax Number	847-789-9274
Product Website	abilifymycitehcp.com

About Opioid Dependence

Opioid dependence is a complex and chronic condition characterized by a person’s reliance on opioids, including prescription painkillers or illicit substances like heroin. Individuals with opioid dependence develop a tolerance to the drug, requiring increased amounts to achieve the desired effects. The compulsion to use opioids persists despite negative consequences, leading to withdrawal symptoms upon cessation. This condition has profound physical, psychological, and social implications, impacting daily functioning and overall well-being.

Opioid Dependence Therapies Supported

Full Name	Sublocade® (buprenorphine extended-release)
Drug	Sublocade
Manufacturer	Indivior
Route of Administration	Subcutaneous
Site of Care	Healthcare Facility
Approved Indication	The treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days
Disease	Opioid Dependence
Therapeutic Area	Mental Health & Addiction
Enrollment Form Link	Sublocade Enrollment Form
Phone Number	800-241-1534
Fax Number	877-785-7737
Product Website	sublocade.com

Full Name	Vivitrol® (naltrexone)
Drug	Vivitrol
Manufacturer	Alkermes
Route of Administration	Intramuscular
Site of Care	Healthcare Facility
Approved Indication	The treatment of alcohol dependence in patients who can abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL; The prevention of relapse to opioid dependence following opioid detoxification
Disease	Alcohol Dependence; Opioid Dependence
Therapeutic Area	Mental Health & Addiction
Enrollment Form Link	Vivitrol Enrollment Form
Phone Number	800-373-1406
Fax Number	847-427-7975, 855-677-4641, 877-496-3716
Product Website	vivitrolhcp.com

About Postpartum Depression (PPD)

Postpartum depression is a specific form of depression occurring after childbirth, presenting similar symptoms. PPD can interfere with a new parent’s ability to care for themselves and their baby. Hormonal fluctuations, sleep deprivation, and the adjustment to parenthood contribute to this condition. Symptoms may include changes in appetite, difficulty bonding with the baby, and overwhelming feelings of guilt.

PPD Therapies Supported

Full Name	Zulresso® (brexanolone)
Drug	Zulresso
Manufacturer	Sage Therapeutics
Route of Administration	Intravenous
Site of Care	Healthcare Facility
Approved Indication	The treatment of postpartum depression (PPD) in adults
Disease	Postpartum Depression
Therapeutic Area	Psychiatry, Mental Health & Addiction
Referral Link	Zulresso Enrollment Form
Phone Number	800-811-6109
Fax Number	877-868-9682
Website	zulresso.com

About Schizophrenia

Schizophrenia is a serious brain illness where people who have it may hear voices that aren’t there, think other people are trying to hurt them, and sometimes don’t make sense when they talk. Because of this, it is hard for people with this infliction to keep a job or take care of themselves. There is no cure, but medicine can help control many of the symptoms.

Schizophrenia Therapies Supported

Full Name	Abilify MyCite® (aripiprazole tablets with sensor)
Drug	Abilify MyCite
Manufacturer	Otsuka Pharmaceutical Co., Ltd.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of adults with schizophrenia, bipolar I disorder, and adjunctive treatment of adults with major depressive disorder (MDD)
Disease	Schizophrenia; Bipolar Disorder; Major Depressive Disorder (MDD)
Therapeutic Area	Psychiatry, Mental Health & Addiction
Enrollment Form Link	Enrollment Form
Phone Number	844-692-4833
Fax Number	847-789-9274
Product Website	abilifymycitehcp.com

About Tardive Dyskinesia (TD)

Tardive dyskinesia is a neurological movement disorder typically characterized by repetitive involuntary movements of the jaw, lips and tongue, and some individuals experience involuntary rapid jerking movements or slow, writhing movements in the arms and legs. The condition is a result of long-term use of certain types of neuroleptics, such as antipsychotics or major tranquilizers.

TD Therapies Supported

Full Name	Austedo® (deutetrabenazine)
Drug	Austedo
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	austedohcp.com

Full Name	Austedo® XR (deutetrabenazine)
Drug	Austedo XR Extended Release
Manufacturer	Teva Neuroscience, Inc.
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for the treatment of Chorea associated with Huntington’s disease and tardive dyskinesia
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-691-0718
Fax Number	877-819-2424
Product Website	www.austedohcp.com

Full Name	Ingrezza® (valbenazine)
Drug	Ingrezza
Manufacturer	Neurocrine Biosciences
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of adults with tardive dyskinesia or chorea associated with Huntington’s disease
Disease	Tardive Dyskinesia (TD); Huntington’s Disease Chorea
Therapeutic Area	Psychiatry, Neurology
Enrollment Form Link	Enrollment Form
Phone Number	800-279-1676
Fax Number	877-868-1681
Product Website	ingrezzahcp.com